MeritValue

BioScience Health Innovations, Inc.

BHICdata completeness 75%7 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

The thesis, from the filings

BioScience Health Innovations, Inc. earns about -175% on equity, but has diluted owners by 109% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2022FY 2022FY 2023FY 2024FY 2025
Revenue$01$69,3432$597,5953$1.84M4$5.69M4
Net income−$83,2085−$170,4506−$251,5007$87,0008$642,0908
Operating cash flow−$85,7829−$182,77910−$307,84211$23,18812$172,17812
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$16,25313$11,56914$19,23815$662,51716$661,92516
Diluted shares5.5M5.5M33.8M10.9M11.4M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$1.3
your share of equity
Profit it earned you last year
$0.56
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $1.3 of net worth that earned you $0.56 last year.

iii. Is this a good business?
Moat signal · return on equity
-175% avg · 5y
FY22 -578%FY22 —FY23 —FY24 10%FY25 43%

It earned an average -175% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+109% shares · 5y

Share count is up 109% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
$0.42
assumptions (1)
  • grahamMultiplier2250.0%

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2022-08-31 · accession 0001185185-22-001245 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001185185-24-000327 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001185185-25-000176 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001185185-26-001133 (Revenues)
  5. 10-K · period ending 2022-08-31 · accession 0001185185-22-001245 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001185185-24-000327 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001185185-25-000176 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001185185-26-001133 (NetIncomeLoss)
  9. 10-K · period ending 2022-08-31 · accession 0001185185-22-001245 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001185185-24-000327 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001185185-25-000176 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001185185-26-001133 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2022-08-31 · accession 0001185185-22-001245 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  14. 10-K · period ending 2022-12-31 · accession 0001185185-24-000327 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-12-31 · accession 0001185185-25-000176 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2024-12-31 · accession 0001185185-26-001133 (CashAndCashEquivalentsAtCarryingValue)